Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Meihua International Medical Technologies Co., Ltd. (MHUAF)
Yangzhou, CN
Meihua International Medical Technologies Co., Ltd. is a Chinese company dedicated to the innovation, production, and distribution of a wide array of medical devices. Operating primarily within the People's Republic of China, its comprehensive product portfolio spans various regulatory classifications. The company offers numerous Class I disposable medical supplies, such as medical X-ray and dry films, dry laser imagers, gauze bandages, and examination gloves. It also provides pharmaceutical packaging, including low-density polyethylene eye drop bottles and high-density polyethylene tablet bottles. Its Class II inventory comprises critical disposable instruments and kits for medical procedures, including complete anesthesia kits, specialized medical brushes, various examination and urethral catheterization sets, endotracheal intubation devices, medical masks, anal bags, and suction connecting tubes. For Class III disposable medical devices, Meihua manufactures advanced solutions like single-use infusion pumps, sophisticated anesthesia puncture kits, and electronic pump systems. Beyond these, the company also produces disposable plastic baby bottles and components like NB/PSN rubber covers and 8.2mL folded spoons for tools and containers. It specializes in Class II 6866 medical polymer materials and products, such as transfusion equipment, pipelines, and endotracheal intubation for respiratory care, alongside traditional medical X-ray films and multi-functional self-extracting X-ray film machines. Meihua caters to a broad customer base, including hospitals, pharmacies, medical institutions, and medical equipment companies. Its products are distributed globally, reaching markets throughout Europe, North America, South America, Asia, Africa, and Oceania. Founded in 1991, the company is headquartered in Yangzhou, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.44% | +0.00% | -4.11% | -6.67% | -29.29% | +309.76% | -81.54% | -97.12% | -99.35% | -99.35% | -99.35% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Instruments & Supplies: +7.9%-36.2% Q4'25: -51.3% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%-54.9% Q4'25: -72.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-1.5% Q4'25: +44.0% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+13.4% Q4'25: +21.2% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+3.3% Q4'25: +7.2% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+37.4% Q4'25: +190.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×1.02× ★ Q4'25: 0.42× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-15 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-08 | A- | 4/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-07 | A- | 4/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-06 | A- | 4/5 | 1/5 | 3/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-23 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-22 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | Wang Ailiang | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Liao Shilong | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Lee Leyi | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Jia Wenzhang | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Gao Chongbo | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Colin Anna | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-28 | Jia Wenzhang | Director | — | — | Option | 19 | 530.00 | 10.1K | 0 | D | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lee Leyi | Chief Executive Officer & Director | — | female |
| Liao Shilong | Chief Financial Officer | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MHUAF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
